Open access
Sep 2026
Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial
Adding bortezomib did not demonstrate a significant efficacy benefit and was associated with a higher incidence of serious adverse events, which was associated with a higher incidence of serious adverse events.
R. Snanoudj, F. Marquant, Karine Renaudin et al.
· Transplant International · 0 citations